Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
28.25
+1.80 (6.81%)
Jul 30, 2026, 4:00 PM EDT - Market closed
Arcus Biosciences Employees
Arcus Biosciences had 601 employees as of December 31, 2025. The number of employees decreased by 26 or -4.15% compared to the previous year.
Employees
601
Change (1Y)
-26
Growth (1Y)
-4.15%
Revenue / Employee
$392,679
Profits / Employee
-$613,977
Market Cap
3.55B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 601 | -26 | -4.15% |
| Dec 31, 2024 | 627 | 50 | 8.67% |
| Dec 31, 2023 | 577 | 77 | 15.40% |
| Dec 31, 2022 | 500 | 134 | 36.61% |
| Dec 31, 2021 | 366 | 130 | 55.08% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Telix Pharmaceuticals | 1,184 |
| Denali Therapeutics | 507 |
| Arcutis Biotherapeutics | 354 |
| Structure Therapeutics | 233 |
| Alumis | 227 |
| IDEAYA Biosciences | 145 |
| Tango Therapeutics | 137 |
RCUS News
- 3 days ago - Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
- 8 days ago - Arcus, Summit enter into clinical trial collaboration over kidney cancer - TheFly
- 8 days ago - Arcus Biosciences announces clinical supply pact with AVEO Oncology - TheFly
- 8 days ago - Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients - Business Wire
- 8 days ago - Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer - Business Wire
- 8 days ago - Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer - Business Wire
- 9 days ago - Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates - Business Wire
- 10 days ago - Arcus Biosciences price target raised to $45 from $32 at H.C. Wainwright - TheFly